日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma

一项 Ib 期多中心、剂量递增研究，旨在评估多胺类似物 PG-11047 联合吉西他滨、多西他赛、贝伐珠单抗、厄洛替尼、顺铂、5-氟尿嘧啶或舒尼替尼治疗晚期实体瘤或淋巴瘤患者的疗效。

期刊:Cancer Chemotherapy and Pharmacology
影响因子:2.3
doi:10.1007/s00280-020-04201-1
Murray Stewart, Tracy; Von Hoff, Daniel; Fitzgerald, Michael; Marton, Laurence J; Becerra, Carlos H Roberto; Boyd, Thomas E; Conkling, Paul R; Garbo, Lawrence E; Jotte, Robert M; Richards, Donald A; Smith, David A; Stephenson, Joe J Jr; Vogelzang, Nicholas J; Wu, Hillary H; Casero, Robert A Jr
淋巴瘤
发表日期：2021
文献求助 收藏

A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer

一项评估瑞法替尼联合索拉非尼治疗晚期癌症患者的安全性、药代动力学和药效学的I期研究

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-15-1681
Adjei, Alex A; Richards, Donald A; El-Khoueiry, Anthony; Braiteh, Fadi; Becerra, Carlos H R; Stephenson, Joe J Jr; Hezel, Aram F; Sherman, Morris; Garbo, Lawrence; Leffingwell, Diane P; Iverson, Cory; Miner, Jeffrey N; Shen, Zancong; Yeh, Li-Tain; Gunawan, Sonny; Wilson, David M; Manhard, Kimberly J; Rajagopalan, Prabhu; Krissel, Heiko; Clendeninn, Neil J
肿瘤
肿瘤免疫
发表日期：2016
文献求助 收藏